Search
Vecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or
Temoporfin
go.drugbank.com/drugs/DB11630ApprovedTemoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label].
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalIn preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.
Nedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigational[A261690] Oxalate, particularly calcium oxalate, precipitation is the main cause of kidney stones formation; therefore, blocking the production of oxalate can help alleviate renal symptoms. … [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary
Fluorescein
go.drugbank.com/drugs/DB00693ApprovedInvestigationalIt has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
Carbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnIt is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.
Estradiol benzoate
go.drugbank.com/drugs/DB13953ApprovedVet approvedWithdrawnAs a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Nitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedNitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular pro...
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigational[L32853] Mirabegron is also used in other jurisdictions across the globe, including Canada,[L32925] the EU,[L32945] and Japan.[A7469] … [L32853] Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder.